AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed.
AZN Key Statistics
AZN News
AstraZeneca's (AZN) Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at the European Society of Medical Onco...
(RTTNews) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on mainte...
Amgen (AMGN) and AstraZeneca (AZN) announced that the U.S. FDA approved Tezspire for the add-on maintenance treatment of inadequately controlled chronic rhinosi...
Analyst ratings
77%
of 31 ratingsMore AZN News
AstraZeneca (AZN) said that Saphnelo has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patient...
(RTTNews) - AstraZeneca (AZN), Friday announced positive Phase III results from its POTOMAC trial, showing that adding one year of treatment with Imfinzi; durva...
Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s (AZN) IMFINZI to BCG induction and maintenance therapy...
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with standard-of-care FLOT c...
AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unloc...
AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unloc...
AstraZeneca Plc got a rare sell rating on Thursday as Deutsche Bank AG analysts downgraded the British drugmaker, taking a more skeptical view on the company’s...
